The optimal conversion ratio between Dysport and Botox—the two botulinum neurotoxin type A products (BoNT-As) supported by the larger bulk of evidence—has been extensively debated, because of its broad medical and economic implications. The article discusses the available evidence on the conversion ratio between Dysport and Botox in adults affected by spasticity, cervical dystonia, blepharospasm and hemifacial spasm, with a focus on clinical trials that specifically addressed this issue. In addition, some suggestions on the conversion ratio between Dysport and Xeomin can be extrapolated, since Xeomin has the same efficacy and safety profile as Botox and is exchangeable with Botox with a 1:1 conversion ratio. Taken together, the findings retrieved from this literature research suggest that a conversion ratio of 3:1 (Dysport:Botox)—or even lower—can be considered appropriate for the treatment of the above-mentioned conditions. Higher conversion ratios may lead to an overdosing of Dysport, with a potential increased incidence of adverse events. Therefore, we recommend that physicians using both products consider using a lower conversion factor as a guide, adjusting it upwards as required based on the specific characteristics and response to treatment of each patient.
Blepharospasm Botulinum toxin Cervical dystonia Conversion ratio Hemifacial spasm Spasticity
This is a preview of subscription content, log in to check access.
Editorial assistance was provided by Luca Giacomelli, PhD, on behalf of inScience Communications, Springer Healthcare. This assistance was funded by Ipsen.
Conflict of interest
Authors declare no conflicts of interest directly relevant to this study.
De Maio M (2008) Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders. Expert Opin Biol Ther 8:791–798PubMedCrossRefGoogle Scholar
Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB (2010) International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments—introduction. Eur J Neurol 17(Suppl 2):1–8PubMedCrossRefGoogle Scholar
Brashear A (2010) Botulinum toxin type A: exploring new indications. Drugs Today (Barc) 46:671–682CrossRefGoogle Scholar
Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25:1573–1584PubMedCrossRefGoogle Scholar
Park J, Lee MS, Harrison AR (2011) Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol 5:725–732PubMedGoogle Scholar
Pickett A (2011) Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data. Clin Ophthalmol 5:1287–1290PubMedCrossRefGoogle Scholar
Jost WH, Blümel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67:669–683PubMedCrossRefGoogle Scholar
Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761–1768PubMedCrossRefGoogle Scholar
Wohlfarth K, Schwandt I, Wegner F et al (2008) Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255:1932–1939PubMedCrossRefGoogle Scholar
Wohlfarth K, Muller C, Sassin I et al (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30:86–94PubMedCrossRefGoogle Scholar
Hesse S, Lücke D, Malezic M et al (1994) Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 57:1321–1324PubMedCrossRefGoogle Scholar
Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA (1996) Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 61:30–35PubMedCrossRefGoogle Scholar
Simpson DM, Alexander DN, O’Brien CF et al (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46:1306–1310PubMedCrossRefGoogle Scholar
Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM (2000) Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 69:217–221PubMedCrossRefGoogle Scholar
Bakheit AM, Thilmann AF, Ward AB et al (2000) A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402–2406PubMedCrossRefGoogle Scholar
Hyman N, Barnes M, Bhakta B et al (2000) Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68:707–712PubMedCrossRefGoogle Scholar
Pittock SJ, Moore AP, Hardiman O et al (2003) A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 15:289–300PubMedCrossRefGoogle Scholar
Woldag H, Hummelsheim H (2003) Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients? Eur Neurol 50:165–171PubMedCrossRefGoogle Scholar
Childers MK, Brashear A, Jozefczyk P et al (2004) Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 85:1063–1069PubMedCrossRefGoogle Scholar
Brin MF (1997) Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl 6:S208–S220PubMedCrossRefGoogle Scholar
Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72:459–462PubMedGoogle Scholar
Odergren T, Hjaltason H, Kaakkola S et al (1998) A , randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6–12PubMedCrossRefGoogle Scholar
Nüssgens Z, Roggenkämper P (1997) Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235:197–199PubMedCrossRefGoogle Scholar
Sampaio C, Ferreira JJ, Simões F et al (1997) DYSPORT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord 12:1013–1018PubMedCrossRefGoogle Scholar
Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2012) Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 33:261–267PubMedCrossRefGoogle Scholar